Clinical Supply Containment Manufacturing 
Pharmaceutical Technology
MAY 24, 2023
Nearly every biopharma with a portfolio of drugs in development spanning traditional small molecules and biologics and the newer CGT operates with separate clinical supply organizations per these therapy areas. This is due to major differences throughout the clinical supply chain in both requirements and management practices.
Pharmaceutical Technology
AUGUST 10, 2022
Working with a contract manufacturing organization (CMO) in the pursuit of bringing a new product to market can deliver a range of significant benefits. Drawings and/or part numbers of the selected container closure? The costing section, meanwhile, should contain technical transfer costs. Packaging needs?.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
SEPTEMBER 20, 2022
Unlike commercial pharmaceutical packaging, the primary consideration in clinical trial packaging is protecting the product quality and reliability for research. Finding the best clinical trial packaging services providers. Clinical trial packaging and labelling solutions.
The Pharma Data
DECEMBER 4, 2021
company (NASDAQ: AMZN), announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. (AWS), an Amazon.com, Inc.
XTalks
JUNE 16, 2023
Concerningly, the survey also revealed that only 40 percent of the surveyed NCCN cancer centers received any indication from manufacturers or suppliers about when carboplatin or cisplatin would be readily available again. Medicines for Europe said the supply issues were evidence of the damaging effects of European cost-containment measures.
The Pharma Data
JANUARY 24, 2021
In clinical research, Cepharanthine exhibits multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties. Sairiyo is currently focused on advancing the clinical development of Cepharanthine to treat rare cancer diseases.
The Pharma Data
NOVEMBER 22, 2020
MP0420 is subject to an option and license agreement with Novartis AG to develop, manufacture and commercialize Molecular Partners’ anti-COVID-19 DARPin® program. All DARPin® candidates are constructed to benefit from high-yield and low-cost microbial manufacturing. Chief Medical Officer of Molecular Partners.
Expert insights. Personalized for you.
246 
Let's personalize your content